Antihypertensive Drugs Therapy in Hypertension and Covid-19 Comorbidity

Emuesiri Goodies Moke, Endurance Efe Ahama, Pere-Ebi Yabrade Toloyai, Mamerhi Taniyohwo Enaohwo, Ekuerhare Basil, Emuesiri Kohworho Umukoro, Anthony Taghogho Eduviere, Ikuesirioghene Udumebraye, Choice Udufowe


The novel coronavirus (CoV) severe acute respiratory syndrome (SARS)-CoV-2 outbreak began at the end of 2019 in Wuhan, China, and has spread to over 200 countries. Many comorbidities have shown to be associated with the severity of the viral infection with hypertension being one of the highest rated comorbidities since loss of the ACE2 receptor due to SARS-Cov-2 infection can lead to increased blood pressure. The effects and clinical characteristics associated with the use of beta-blockers, angiotensin receptor blockers (ARB), and calcium-channel blockers (CCB) shows not to affect the outcome of covid-19, except in angiotensin converting enzyme inhibitor (ACEI) which may have negative outcomes on covid-19 infected patients. Many comorbidities have shown to be associated with the severity of the viral infection.

Full Text:



Abayomi A, Osibogun A, Kanma-Okafor O, Idris J, Bowale A, Wright O, Adebayo B, Balogun M, Ogboye S, Adeseun R, Abdus-Salam I, Mutiu B, Saka B, Lajide D, Yenyi S, Agbolagorite R, Onasanya O, Erinosho E, Obasanya J, Adejumo O, Adesola S, Oshodi Y, Akase IE, Ogunbiyi S, Omosun A, Erinoso F, Abdur-Razzaq H, Osa N, Akinroye K (2021). Morbidity and mortality outcomes of COVID-19 patients with and without hypertension in Lagos, Nigeria: a retrospective cohort study. Glob Health Res Policy 6(1):26.

Acelajado MC, Hughes ZH, Oparil S, Calhoun DA (2019). Treatment of Resistant and Refractory Hypertension. Circ Res 124(7): 1061-1070.

Alawode DI, Asiwe JN, Moke EG, Okonofua DE, Sanusi KO, Adagbada EO, Yusuf MO,

Fasanmade AA (2021). The Effect of Ethanol Leaf Extract of Cnidosculus Aconitifolius on Cardiorenal Functions in Hypertensive and Normotensive Male Wistar Rats. Int J Nutr Sci 6(3):155-160.

Armstrong C., Joint National Committee (2014). JNC8 guidelines for the management of hypertension in adults. Am Fam Physician 90(7):503-504.

Barrera FJ, Shekhar S, Wurth R, Moreno-Pena PJ, Ponce OJ, Hajdenberg M, Alvarez-Villalobos NA, Hall JE, Schiffrin EL, Eisenhofer G, Porter F, Brito JP, Bornstein SR, Stratakis CA, González-González JG, Rodíguez-Gutiérrez R, Hannah-Shmouni F (2020). Prevalence of Diabetes and Hypertension and Their Associated Risks for Poor Outcomes in Covid-19 Patients. J Endocr Soc 4(9):bvaa102. doi: 10.1210/jendso/bvaa102. Erratum in: J Endocr Soc. 5(1):bvaa175.

Batiha GE, Gari A, Elshony N, Shaheen HM, Abubakar MB, Adeyemi SB, Al-Kuraishy HM (2021). Hypertension and its management in COVID-19 patients: The assorted view. Int J Cardiol Cardiovasc Risk Prev 11:200121.

Bauer AZ, Gore R, Sama SR, Rosiello R, Garber L, Sundaresan D, McDonald A, Arruda P, Kriebel D (2021). Hypertension, medications, and risk of severe COVID-19: A Massachusetts community-based observational study. J Clin Hypertens (Greenwich) 23(1):21-27.

Booth A, Reed AB, Ponzo S, Yassaee A, Aral M, Plans D, Labrique A, Mohan D (2021). Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis. PLoS One 16(3):e0247461.

Cancarevic I, Malik BH (2020). SARS-CoV-2 (COVID 19) Infection in Hypertensive Patients and in Patients With Cardiac Disease. Cureus 12(6):e8557.

Carey RM (2020). Special Article – The management of resistant hypertension: A 2020 update. Prog Cardiovasc Dis 63(5): 662-670.

Carfora V, Spiniello G, Ricciolino R, Di Mauro M, Migliaccio MG, Mottola FF, Verde N, Coppola N; Vanvitelli COVID-19 group (2021). Anticoagulant treatment in COVID-19: a narrative review. J Thromb Thrombolysis 51(3):642-648.

Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, Xing F, Liu J, Yip CC, Poon RW, Tsoi HW, Lo SK, Chan KH, Poon VK, Chan WM, Ip JD, Cai JP, Cheng VC, Chen H, Hui CK, Yuen KY (2020). A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 395(10223):514-523.

Cook TM (2020). The importance of hypertension as a risk factor for severe illness and mortality in COVID-19. Anaesthesia 75(7):976-977.

Elliott WJ, Ram CV (2011). Calcium channel blockers. J Clin Hypertens (Greenwich) 13(9):687-9.

Enaohwo TM, Ikpama W, Okoro OG, Moke EG (2021). An Investigation on COVID-19 in Nigeria and Relationship with Age Groups. Int J Human Health Sci 5(3): 292-296

Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K (2016). Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 387(10022):957-967

Farzam K, Jan A (2020). Beta blockers. StatPearls Publishing, Treasure Island, FL, USA.

Forrester SJ, Booz GW, Sigmund CD, Coffman TM, Kawai T, Rizzo V, Scalia R, Eguchi S (2018). Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology. Physiol Rev 98(3):1627-1738.

Frishman WH, Saunders E (2011). ?-Adrenergic blockers. J Clin Hypertens (Greenwich) 13(9):649-53.

Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, Liu XQ, Chen RC, Tang CL, Wang T, Ou CQ, Li L, Chen PY, Sang L, Wang W, Li JF, Li CC, Ou LM, Cheng B, Xiong S, Ni ZY, Xiang J, Hu Y, Liu L, Shan H, Lei CL, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Cheng LL, Ye F, Li SY, Zheng JP, Zhang NF, Zhong NS, He JX; China Medical Treatment Expert Group for COVID-19 (2020). Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J 55(5):2000547.

Guo X, Zhu Y, Hong Y (2020). Decreased Mortality of COVID-19 With Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients With Hypertension: A Meta-Analysis. Hypertension 76(2):e13-e14.

Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C, Pöhlmann S (2020). SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 181(2):271-280.e8.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395(10223):497-506.

Hui DS, I Azhar E, Madani TA, Ntoumi F, Kock R, Dar O, Ippolito G, Mchugh TD, Memish ZA, Drosten C, Zumla A, Petersen E (2020). The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis 91:264-266.

Jackson, RE, Bellamy, MC (2015). Antihypertensive drugs. BJA Education; 15(6):280–285

Khalil H, Zeltser R (2020). Antihypertensive Medications, StatPearls Publishing, Treasure Island, FL, USA. Available from:

Kjeldsen SE, Narkiewicz K, Burnier M, Oparil S (2021). Potential protective effects of antihypertensive treatments during the Covid-19 pandemic: from inhibitors of the renin-angiotensin system to beta-adrenergic receptor blockers. Blood Press 30(1):1-3.

Kuo IY, Ehrlich BE (2015). Signaling in muscle contraction. Cold Spring Harb Perspect Biol 7(2):a006023.

Lei J, Kusov Y, Hilgenfeld R (2018). Nsp3 of coronaviruses: Structures and functions of a large multi-domain protein. Antivir Res 149:58–74.

Leiva Sisnieguez CE, Espeche WG, Salazar MR (2020). Arterial hypertension and the risk of severity and mortality of COVID-19. Eur Respir J 55(6):2001148.

Letko M, Marzi A, Munster V (2020). Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol 5:562–569.

Loas G, Van de Borne P, Darquennes G, Le Corre P (2022). Association of Amlodipine with the Risk of In-Hospital Death in Patients with COVID-19 and Hypertension: A Reanalysis on 184 COVID-19 Patients with Hypertension. Pharmaceuticals (Basel) 15(3):380.

Lu R., Zhao X., Li J., Niu P., Yang B., Wu H., Wang W., Song H., Huang B., Zhu N., et al (2020). Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet 395:565–574.

Malik YA (2020). Properties of Coronavirus and SARS-CoV-2. Malays J Pathol 42(1):3-11.

McKeever RG, Hamilton RJ (2022). Calcium Channel Blockers. [Updated 2022 Jul 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from:

Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, Chen J, He J (2016). Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries. Circulation 134(6):441-50.

Mills KT, Stefanescu A, He J (2020) The global epidemiology of hypertension. Nat Rev Nephrol 16:223-37.

Moftakhar L, Piraee E, Mohammadi Abnavi M, Moftakhar P, Azarbakhsh H, Valipour A (2021). Epidemiological Features and Predictors of Mortality in Patients with COVID-19 with and without Underlying Hypertension. Int J Hypertens 2021:7427500.

Moke EG, Ekuerhare B, Enaohwo MT, Asiwe JN, Ofulue OO, Umukoro EK, Isibor NP (2022). Resistant hypertension. J Drug Deliv Ther 12, 230–235.

Nelson M (2010). Drug treatment of elevated blood pressure. Aust Prescr 33: 108–112.

Noh J, Kim HC, Shin A, Yeom H, Jang SY, Lee JH, Kim C, Suh I (2016). Prevalence of Comorbidity among People with Hypertension: The Korea National Health and Nutrition Examination Survey 2007-2013. Korean Circ J 46(5):672-680.

Nouri-Vaskeh M, Kalami N, Zand R, Soroureddin Z, Varshochi M, Ansarin K, Rezaee H, Taghizadieh A, Sadeghi A, Ahangari Maleki M, Esmailnajad A, Saleh P, Haghdoost M, Maleki M, Sharifi A (2021). Comparison of losartan and amlodipine effects on the outcomes of patient with COVID-19 and primary hypertension: A randomised clinical trial. Int J Clin Pract 75(6):e14124.

Okonofua DE, Asiwe JN, Anachuna KK, Moke EG, Sanusi KO, Adagbada EO, Yusuf MO, Alawode DI, Fasanmade AA (2021). Effect of Diabetes Mellitus and Hypertension on Osmotic Fragility and Hemorheological Factors in Male Wistar Rats. Biol Med Natural Prod Chem 10(2):73-79

Omo-Aghoja L, Moke EG, Anachuna KK, Omogbiya AI, Umukoro EK, Toloyai PY, Daubry TME, Eduviere AT (2021). COVID-19 pandemic: the implications of the natural history, challenges of diagnosis and management for care in sub-Saharan Africa. Beni-Suef University J Basic Appl Sci 10(1):1-16.

Osibogun A, Balogun M, Abayomi A, Idris J, Kuyinu Y, Odukoya O, Wright O, Adeseun R, Mutiu B, Saka B, Osa N, Lajide D, Abdus-Salam I, Osikomaiya B, Onasanya O, Adebayo B, Oshodi Y, Adesola S, Adejumo O, Erinoso O, Abdur-Razzaq H, Bowale A, Akinroye K (2021). Outcomes of COVID-19 patients with comorbidities in southwest Nigeria. PLoS One 16(3):e0248281.

Pal M, Berhanu G, Desalegn C, Kandi V (2020). Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): An Update. Cureus 12(3):e7423.

Patel AB, Verma A (2020). COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence? JAMA 323(18):1769-1770.

Phan T (2020). Novel coronavirus: From discovery to clinical diagnostics. Infect Genet Evol 2020;79

Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, Hausvater A, Newman JD, Berger JS, Bangalore S, Katz SD, Fishman GI, Kunichoff D, Chen Y, Ogedegbe G, Hochman JS (2020). Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19. N Engl J Med 382(25):2441-2448.

Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW; the Northwell COVID-19 Research Consortium; Barnaby DP, Becker LB, Chelico JD, Cohen SL, Cookingham J, Coppa K, Diefenbach MA, Dominello AJ, Duer-Hefele J, Falzon L, Gitlin J, Hajizadeh N, Harvin TG, Hirschwerk DA, Kim EJ, Kozel ZM, Marrast LM, Mogavero JN, Osorio GA, Qiu M, Zanos TP (2020). Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA 323(20):2052-2059.

Ruscitti P, Berardicurti O, Di Benedetto P, Cipriani P, Iagnocco A, Shoenfeld Y, Giacomelli R (2020). Severe COVID-19, Another Piece in the Puzzle of the Hyperferritinemic Syndrome. An Immunomodulatory Perspective to Alleviate the Storm. Front Immunol 11:1130.

Schmieder RE, Ruilope LM (2008). Blood pressure control in patients with comorbidities. J Clin Hypertens (Greenwich) 10(8):624-31.

Solaimanzadeh I (2020). Nifedipine and Amlodipine Are Associated With Improved Mortality and Decreased Risk for Intubation and Mechanical Ventilation in Elderly Patients Hospitalized for COVID-19. Cureus 12(5):e8069.

Solanki N, Pandit D, Desai S (2021). Effectiveness and safety assessment of beta-blockers, calcium channel blockers, and angiotensin receptor blockers in hypertensive patients: a prospective study. Am J Cardiovasc Dis 11(5):601-610.

Stanaway JD, et al; GBD 2017 Risk Factor Collaborators (2018). Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392(10159):1923-1994. Erratum in: Lancet. 2019;393(10167):132. Erratum in: Lancet 2019;393(10190):e44.

Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, Ramirez A, Schlaich M, Stergiou GS, Tomaszewski M, Wainford RD, Williams B, Schutte AE (2020). 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension 75(6):1334-1357.

Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD (2020). Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med 382(17):1653-1659.

Vasanthakumar N (2020). Beta-Adrenergic Blockers as a Potential Treatment for COVID-19 Patients. Bioessays. 42(11):e2000094.

Wang JJ, Edin ML, Zeldin DC, Li C, Wang DW, Chen C (2020). Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities. Pharmacol Ther 215:107628.

Wiysonge CS, Bradley HA, Volmink J, Mayosi BM, Mbewu A, Opie LH (2017). Beta-blockers for hypertension. Cochrane Database Syst Rev 11:CD002003.

World Health Organization (WHO) (2021). Hypertension. Available from:

Yadav R, Chaudhary JK, Jain N, Chaudhary PK, Khanra S, Dhamija P, Sharma A, Kumar A, Handu S (2021). Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19. Cells 10(4):821.

Zhang LK, Sun Y, Zeng H, Wang Q, Jiang X, Shang WJ, Wu Y, Li S, Zhang YL, Hao ZN, Chen H, Jin R, Liu W, Li H, Peng K, Xiao G (2020). Calcium channel blocker amlodipine besylate therapy is associated with reduced case fatality rate of COVID-19 patients with hypertension. Cell Discov 6(1):96.

Zou Z, Yan Y, Shu Y, Gao R, Sun Y, Li X, Ju X, Liang Z, Liu Q, Zhao Y, Guo F, Bai T, Han Z, Zhu J, Zhou H, Huang F, Li C, Lu H, Li N, Li D, Jin N, Penninger JM, Jiang C (2014). Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections. Nat Commun 5:3594.



  • There are currently no refbacks.

Copyright (c) 2023 Emuesiri Goodies Moke, Endurance Efe Ahama, Pere-Ebi Yabrade Toloyai, Mamerhi Taniyohwo Enaohwo, Ekuerhare Basil, Emuesiri Kohworho Umukoro, Anthony Taghogho Eduviere, Ikuesirioghene Udumebraye, Choice Udufowe

Biology, Medicine, & Natural Product Chemistry
ISSN 2089-6514 (paper) - ISSN 2540-9328 (online)
Published by Sunan Kalijaga State Islamic University & Society for Indonesian Biodiversity.

Creative Commons License
This work is licensed under a CC BY-NC